Front Row Advisors’s Arbutus Biopharma ABUS Stock Holding History

Front Row Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$516K	Hold	110,500	–	–	0.15%	76
2026 Q1	$497K	Buy	110,500 +100,000	+952%	+$437K	0.17%	75
2025 Q4	$50.5K	Hold	10,500	–	–	0.02%	217
2025 Q3	$47.7K	Hold	10,500	–	–	0.02%	221
2025 Q2	$32.4K	Hold	10,500	–	–	0.01%	242
2025 Q1	$36.6K	Hold	10,500	–	–	0.01%	241
2024 Q4	$34.3K	Hold	10,500	–	–	0.01%	250
2024 Q3	$40.4K	Hold	10,500	–	–	0.01%	237
2024 Q2	$32.4K	Hold	10,500	–	–	0.01%	326
2024 Q1	$27.1K	Hold	10,500	–	–	0.01%	341
2023 Q4	$26.3K	Hold	10,500	–	–	0.01%	228
2023 Q3	$21.3K	Hold	10,500	–	–	0.01%	371
2023 Q2	$24K	Hold	10,500	–	–	0.01%	339
2023 Q1	$32K	Hold	10,500	–	–	0.02%	292
2022 Q4	$24K	Hold	10,500	–	–	0.01%	338
2022 Q3	$20K	Hold	10,500	–	–	0.01%	376
2022 Q2	$28K	Hold	10,500	–	–	0.01%	315
2022 Q1	$31K	Buy	+10,500	New	+$32.1K	0.01%	324

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Front Row Advisors's ABUS Position: Q2 2026 in Review

Front Row Advisors held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 110,500 shares worth $516K. The position accounts for 0.15% of the portfolio, ranked #76.

Front Row Advisors first reported a position in ABUS in Q1 2022 and has held it in 18 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Front Row Advisors held 110,500 shares of Arbutus Biopharma worth $516K as of Q2 2026.
Front Row Advisors left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up 0.15% of Front Row Advisors's portfolio in Q2 2026, its #76 holding.
Front Row Advisors first reported a position in Arbutus Biopharma in Q1 2022 and has held it in 18 quarters since.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.